- pre-open

Other headlines for [WX]

• WX Today 05:02am
  Wuxi Pharmatech Inc ADR Plans to discontinue biologics manufacturing, focus on laboratory testing- Sees $2.5-3.5M one off charge. - To eleminate positions through attrition and cuts.
  
• WX 11/13/2008 10:18am
  Wuxi Pharmatech Inc ADR Price Target lowered to $12 from $14 at Merrill, maintains buy rating
  
• WX 11/12/2008 07:00pm
  Wuxi Pharmatech Inc ADR Reports Q3 $0.10 v $0.09e, R $67.5M v $68.4Me- Reaffirms FY08 R $260-265M v 265.6Me as stated on 10/14. This represents y/y revenue growth ranging from 92% to 96%.
  
• WX 11/7/2008 02:14am
  Wuxi Pharmatech Inc ADR Signs new collaboration agreement with Pfizer- Co has signed a new three-year, in vitro ADME collaboration agreement with Pfizer. - Terms not disclosed
  
• WX 10/16/2008 03:34am
  Wuxi Pharmatech Inc ADR Expands collaboration for fully integrated services with Johnson & Johnson- Co has reached an agreement with Johnson & Johnson Pharmaceutical Research & Development, Division of Janssen more...
  

Healthcare sector headlines

• MAKO Today 07:46am
  MAKO Surgical Receives FDA Clearance to Market Both Its Version 2.0 Tactile Guidance System and Its Bicompartmental Knee Resurfacing Implant System- Announced it received two 510(k) clearances from the US FDA to more...
  
• UNH Today 07:40am
  UnitedHealth Group Inc Guides 2009 Commercial Enrollment down 1-1.5M y/y; Full year decline of 450-800K commercial risk based members- Sees 2009 Medicare advantage enrollemnt up 10-135K y/y - Sees 2009 Medicade more...
  
• MYL Today 07:30am
  Mylan Laboratories Inc Announces settlement agreement with Novartis related to Femara First-to-File Opportunity- Under the agreement, Mylan is provided a patent license that will enable the company to market Letrozole more...
  
• XNPT Today 07:30am
  XenoPort Inc Reports Results from a Phase 2 Clinical Trial of XP19986 as a Treatment for the Symptoms of Gastroesophageal Reflux Disease- The primary analysis comparing XP19986 to placebo did not reach more...
  
• TGEN Today 07:30am
  Targeted Genetics Corp Realigns product development priorities; Implements cost reduction measures- To focus on its ocular and neurological product candidates and its first use of expressed RNAi - Company has reduced its more...